TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tiziana Life Sciences ( (TLSA) ) has provided an update.
On December 2, 2025, Tiziana Life Sciences announced its intention to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, into a separate publicly traded company. This strategic move aims to enhance the focus of each company and drive shareholder value, with Tiziana shareholders retaining value through distribution in specie of shares in the new entity. The decision is influenced by increased industry interest in IL-6 pathway therapeutics, highlighted by Novartis’ recent acquisition of Tourmaline Bio. The spinout will allow Tiziana to concentrate on its lead program, intranasal foralumab, while dedicating resources to the development of TZLS-501.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulation therapies. The company employs transformational drug delivery technologies, particularly emphasizing intranasal delivery methods. Tiziana’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, aiming to treat neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 332,269
Technical Sentiment Signal: Buy
Current Market Cap: $199.5M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.